Transcarent, a digital health platform, completed its merger with Accolade, a virtual healthcare company, for $621 million. Accolade shareholders received $7.03 per share. As of April 7, Accolade’s stock price was $7.02. The merger was financed by General Catalyst, 62 Ventures, and other investors. Transcarent focuses on oncology, surgery, and weight health, while Accolade enhances health plans and employer benefits. The combined entity will serve 20 million members and over 1,700 customers. Transcarent’s AI-powered WayFinding and pharmacy benefits will integrate with Accolade’s healthcare advocacy and virtual care services. In 2024, Transcarent raised $126 million in a Series D round, bringing its total funding to $450 million and valuation to $2.2 billion. In 2023, Transcarent partnered with ViewFi for virtual orthopedic care and acquired 98point6’s assets for up to $100 million. That year, Accolade reduced its workforce and office space as part of strategic adjustments.
Douglas Steinhardt
@DSteinhardtEsq
·
Apr 7 The NJ Turnpike Authority handed a $1.73 BILLION contract—and access to sensitive EZ-Pass data—to a company with ties to Communist China.
A Newark-based firm offered to do it for $250M less.
Why was TransCore chosen?
Who’s protecting NJ drivers?
I want answers. #china #nj
Accolade
@Accolade
·
Apr 8 We’re thrilled to announce that
@Transcarent
has successfully completed its merger with Accolade.Together, we offer unmatched choice, better health outcomes, & significantly reduce costs.We are the One Place for Health and Care!#OnePlaceForHealth
Transcarent
@transcarent
·
22h A new era in health and care starts here and it’s all about the experience!Together, Transcarent &
@Accolade
are going beyond navigation to be the first place people go to find answers, take action & get care in the moments that matter.http://bit.ly/42kTUzp
Wake Up NJ New Jersey
@wakeupnj
·
Apr 6 Why do we still have barely any answers about how a Chinese company TransCore was awarded a $1.73 billion contract last year to handle NJ E-ZPassAll while Newark based company Conduent bid was $251 million lower than TransCore’s dealWho approved this and why?!
Transcarent
@transcarent
·
Apr 8 Together, Transcarent &
@Accolade
are the One Place for Health and Care. We’re thrilled to announce the successful completion of our merger!Together, we offer unmatched choice, better health outcomes, and significantly reduced costs.
https://bit.ly/4iYRdKS#OnePlaceForHealth
Accolade
@Accolade
·
22h Together,
@Transcarent
and Accolade are going beyond navigation to deliver an experience that people love, giving them the choice, clarity, and confidence they need to find answers, take action, and get care in the moments that matter. #OnePlaceForHealthhttps://accd.co/4j2f3FS
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
